The WID®-easy test

The WID®-easy test looks for specific changes in the DNA in a cervicovaginal sample. DNA carries the genetic instructions for our bodies and is like a biological “blueprint.” The WID®-easy test is designed to detect changes in specific parts of the DNA associated with womb cancer.

Previous studies including more than 2,500 participants have shown the WID®-easy test to be as good as an ultrasound at detecting womb cancer and would reduce the number of women who need further invasive tests. Many scientific papers have been published describing these previous studies.

The test was developed by Professor Martin Widschwendter and his teams at University College London and the University of Innsbruck. The technology is licensed to Sola Diagnostics.

To read more about the test, click on the titles below:

Iona Evans, Dan Reisel, Allison Jones, Alba Bajrami et al, Performance of the WID-qEC test versus sonography to detect uterine cancers in women with abnormal uterine bleeding (EPI-SURE): a prospective, consecutive observational cohort study in the UK. Lancet Oncology 2023.

Elisa Redl, Chiara Herzog, Charlotte Vavourakis et al, The cervico-vaginal DNA methylation WID-qEC test: An epigenetic marker associated with ovarian cancer in the absence of endometrial and cervical cancer. International Journal of Cancer 2026.

Sebastian Ken-Amoah, Elisa Redl et al. Performance of the WID-qEC test to detect uterine cancers in black women with abnormal uterine bleeding: A prospective observational cohort study in Ghana. International Journal of Cancer, 2025.

Ojone Illah, Malcolm Scott, Elisa Redl et al. High performance of the DNA methylation-based WID-qECtest for detecting uterine cancers independent ofsampling modalities. International Journal of Cancer, 2024.

Lena Schreiberhuber et al, The WID-qEC test: Performance in a hospital-based cohort and feasibility to detect endometrial and cervical cancers. International Journal of Cancer, 2022.

Chiara Herzog, Fatima Marin et al. A Simple Cervicovaginal Epigenetic Test for Screening and Rapid Triage of Women With Suspected Endometrial Cancer: Validation in Several Cohort and Case/Control Sets. Journal of Clinical Oncology, 2022.